2021
Status epilepticus as a complication after COVID-19 mRNA-1273 vaccine: A case report
SIN, Robin a Denisa ŠTRUNCOVÁZákladní údaje
Originální název
Status epilepticus as a complication after COVID-19 mRNA-1273 vaccine: A case report
Autoři
SIN, Robin (203 Česká republika) a Denisa ŠTRUNCOVÁ (203 Česká republika, garant, domácí)
Vydání
World Journal of Clinical Cases, PLEASANTON, BAISHIDENG PUBLISHING GROUP INC, 2021, 2307-8960
Další údaje
Jazyk
angličtina
Typ výsledku
Článek v odborném periodiku
Obor
30218 General and internal medicine
Stát vydavatele
Spojené státy
Utajení
není předmětem státního či obchodního tajemství
Odkazy
Impakt faktor
Impact factor: 1.534
Kód RIV
RIV/00216224:14110/21:00124181
Organizační jednotka
Lékařská fakulta
UT WoS
000727979500031
Klíčová slova anglicky
SARS-CoV-2; COVID-19; mRNA vaccine; Complication of vaccination; Status epilepticus; Case report
Příznaky
Mezinárodní význam, Recenzováno
Změněno: 3. 3. 2022 13:21, Mgr. Tereza Miškechová
Anotace
V originále
BACKGROUND We present a rare case of status epilepticus in a 56-year-old man which arose as a complication after vaccination with the coronavirus disease 2019 (COVID-19) mRNA-1273 vaccine. The patient's history included well-compensated secondary epilepsy. The root cause of the situation was a fever which had developed as a side effect of the vaccination. CASE SUMMARY A 56-year-old man received the first dose of mRNA-1273 vaccine against the severe acute respiratory syndrome-coronavirus-2. The vaccine was administered intramuscularly (100 mg, 0.5 mL). The next morning the man was found to be suffering from fever and headaches while at the same time experiencing general weakness. He lost consciousness suddenly and experienced generalized clonic seizures which turned into status epilepticus. When the Emergency Medical Service arrived the patient was unconscious with spontaneous breathing and generalized clonic seizures. It was necessary to administer diazepam repeatedly. It was also necessary to administer high doses of levetiracetam and temporary propofol. The status epilepticus was brought under control approximately 90 min after the patient's transport to the Emergency Department. A follow-up electroencephalogram no longer revealed abnormal indications of epileptic fit. The patient was temporarily hospitalized in the Intensive Care Unit and after seven days care was discharged without any further apparent effects. CONCLUSION There is currently no specific treatment against COVID-19. Therefore, the benefits of COVID-19 vaccine protection outweigh the risks.